Segall Bryant & Hamill LLC Decreases Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Segall Bryant & Hamill LLC lowered its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 8.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 516,877 shares of the biotechnology company’s stock after selling 45,898 shares during the quarter. Segall Bryant & Hamill LLC owned 0.36% of Aurinia Pharmaceuticals worth $4,642,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $25,000. Blue Trust Inc. increased its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the last quarter. FMR LLC raised its position in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares during the period. Virtu Financial LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth $96,000. Finally, Union Bancaire Privee UBP SA bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $108,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

NASDAQ AUPH opened at $8.46 on Friday. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -56.40 and a beta of 1.26. The company’s 50 day moving average is $8.09 and its two-hundred day moving average is $8.02.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday.

Insider Activity

In related news, insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the sale, the insider now owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph M. Miller sold 61,859 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. This represents a 8.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock worth $2,753,094 in the last three months. Company insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.